Table III.

Age-specific and total prevalence rates self-reported health outcomes/risk factors in males by majority/minority area and discrimination status

	Minority area					Majority area
	Discriminated					Discriminated
	Against		not			Against		not
	n	%	n	%	Pa	n	%	n	%	Pa
Cardiovascular disease
36–49 years	3	3.8	4	1.5	0.22	4	3.5	8	3.3	0.92
50–59 years	18	21.2	32	11.0	0.02	12	13.2	22	10.4	0.48
60–79 years	23	31.5	102	30.9	0.92	24	31.2	55	26.4	0.43
Total crude	44	18.5	138	15.6	0.29	40	14.2	85	12.8	0.58
Total age-adjustedb	44	15.1	138	10.6	0.05	40	11.3	85	9.2	0.29
Chronic muscle pain
36–49 years	28	34.1	83	31.7	0.68	33	30.0	73	30.8	0.88
50–59 years	44	51.6	120	40.7	0.20	47	50.5	79	38.0	0.42
60–79 years	32	44.4	122	37.9	0.30	32	43.8	66	32.2	0.07
Total crude	104	42.4	325	37.0	0.12	112	40.6	218	33.5	0.04
Total age-adjustedb	104	42.3	325	36.5	0.09	112	40.5	218	33.3	0.04
Diabetes
36–49 years	5	6.2	5	1.9	0.04	2	1.8	3	1.2	0.70
50–59 years	9	10.7	16	5.5	0.09	7	7.8	13	6.1	0.60
60–79 years	15	20.8	31	9.4	0.01	5	6.4	17	8.3	0.61
Total crude	29	12.2	52	5.9	0.001	14	5.0	33	5.0	0.98
Total age-adjustedb	29	11.1	52	4.8	0.001	14	4.5	33	4.3	0.91
Obesity
36–49 years	14	17.3	38	14.2	0.50	21	18.4	29	11.9	0.10
50–59 years	18	19.6	43	14.7	0.26	19	21.1	32	15.4	0.23
60–79 years	17	23.3	65	19.9	0.51	17	23.0	26	12.6	0.03
Total crude	49	19.9	146	16.5	0.20	57	20.5	87	13.2	0.005
Total age-adjustedb	49	19.8	146	15.9	0.17	57	20.3	87	13.2	0.006
Metabolic syndrome
36–49 years	7	9.7	9	3.9	0.05	6	6.1	9	4.1	0.45
50–59 years	4	5.4	14	5.6	0.96	9	11.4	15	8.1	0.39
60–79 years	6	10.3	23	8.3	0.61	4	6.8	8	4.4	0.47
Total crude	17	8.3	46	6.0	0.24	19	8.0	32	5.5	0.17
Total age-adjustedb	17	8.2	46	5.6	0.2	19	7.9	32	5.4	0.18

^ap Values from likelihood ratio tests for difference between discriminated against and not discriminated against groups. p Values in bold indicate significant difference between discriminated against and not discriminated against groups equal or higher than<0.05 level.

^bThe age-adjusted probabilities are based on logistic regression estimates.